Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

r the three and nine months ended September 30, 2011 includes a $16.2 million in-process research and development asset impairment charge.Conference CallMylan will host a conference call and live audio webcast today, Wednesday, October 26, 2011, at 8:30 a.m. ET, in conjunction with the release of its financial results.  The dial-in number to access the call is 877.402.3913 or 817.382.5964 for international callers. A replay, available for approximately seven days, will be available at 800.585.8367 or 404.537.3406 for international callers with access pass code 12176566. To access a live audio webcast of the call, please log on to Mylan's website (www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately seven days.

About MylanMylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

Forward Looking StatementsThis press release includes statements that constitute "forward-looking statements", including with regard to the company's future operations, its earnings expectations, its growth targets and anticipated product launches. These statements are made pursuant to the safe harbor provisions of the Pr
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that it will ... operating results on Tuesday, March 10, 2015 after the ... host a conference call and webcast on Tuesday, March ... Pacific to discuss the results and recent corporate developments. ...
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy , ... The GMO TRUTH podcast on both ITunes and at The ... mission to discover the truth and change the world. ... truth about the GMOs in our food supply,” adds a ... an expansion of the documentary/investigative film-making methodology in place at ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... Wis. - Mirus Bio Corp. , a Madison-based ... first outside the U.S., that covers a method of treating ... of genes. , ,The patent, titled "Intravascular Delivery of Nucleic ... therapeutic nucleic acids to body tissues via the blood stream ...
... in an elevator next to a venture capitalist who could ... thing about it yet. , ,You have 90 seconds ... Elevator Pitch Olympics, a yearly event at the Wisconsin ... dished out advice and a few hard knocks to hopeful ...
... and - to paraphrase Sally Field - "You like us, you ... there was a keen observation: that some of the companies debuted ... some of the technologies on the DEMO stage. Yet I suspect ... might argue, does not a company make. Or perhaps I should ...
Cached Biology Technology:Mirus granted European patent for gene therapy 29 tips for making 90 seconds count in an investment pitch 2Sometimes, features can make a company 2Sometimes, features can make a company 3
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... published in the November issue of Nutrition Journal ... may have helped healthy, overweight people feel more satisfied and ... study was funded by the Hass Avocado Board. The ... Effect of Hass Avocado Intake on Post Ingestive Satiety, Glucose ...
... the relative rate of molecular evolution between humans and chimps with ... marches on at a steady pace in all creatures or if ... genetic code occur more rapidly in some groups than in ... Proceedings of the Royal Society B . The team chose ...
... 2014 Despite years of anti-smoking education and legislation, ... in the United States. In 2010, 25.2% of all ... use. While anti-tobacco efforts continue across the county, the ... a less harmful alternative to cigarettes and also as ...
Cached Biology News:New research: Effects of eating half an avocado with lunch on satiety & desire to eat between meals 2Of lice and men (and chimps): Study tracks pace of molecular evolution 2Of lice and men (and chimps): Study tracks pace of molecular evolution 3Perceived benefits of e-cigarettes may lead to higher experimentation rates 2Perceived benefits of e-cigarettes may lead to higher experimentation rates 3
... Workstation is a modular, highly scalable, automated ... 1ml or 3ml industry standard SPE cartridges, ... samples in less than two hours unattended. ... cartridges, and up to 10 modules can ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... evolutionarily conserved form of cell suicide, which ... central component of this process is a ... These enzymes participate in a series of ... pro-apoptotic signals and result in the cleavage ...
... DNA Visualizer Extraction Kit is manufactured ... causing DNA damage byexposure to UV light. ... gel is often used for DNA-cloning work. ... ethidium bromide and exposure of UV light ...
Biology Products: